Recent Updates
Recently added Catalysts
OCGN Positive Sentiment

Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4

Key Takeaway: Ocugen, Inc. will host a conference call on November 4, 2026, to discuss its business update and third quarter financial results. The call will begin at 8:30 a.m. ET, with materials available on the investor website. The company focuses on gene therapies for blindness diseases, aiming to address significant medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ocugen will provide a business update and Q3 results.
  • The company is a leader in gene therapies for blindness.
  • Ocugen's therapies target multiple gene networks.
  • Significant unmet medical needs are being addressed.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+132%
120-day peak, hindsight
Typical move
5.2%
average across 11 past catalysts
Cash runway
~22 mo
Low dilution risk
Lead asset
OCU410
Phase 3 · Dry Age-related Macular Degeneration

Full Press Release Details

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call.
Conference Call Details Date: Wednesday, November 4, 2026 Time: 8:30 a.m. ET Webcast: https://edge.media-server.com/mmc/p/w8rytgud Participant Event Dial-ins: +1(800)715-9871 for US callers and +1(646)307-1963 for international callers Participant Access Code: 6835403
A replay of the call and archived webcast will be available on the Ocugen investor website.
About Ocugen, Inc. Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow Ocugen on LinkedIn and X. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Investors: Candice Masse astr partners candice.masse@astrpartners.com

Media: Chris Clark VP Communications, Ocugen chris.clark@ocugen.com

Frequently Asked Questions

When will Ocugen provide its Q3 2026 financial results?

Ocugen will provide its Q3 2026 financial results on November 4, 2026.

What is the focus of Ocugen's therapies?

Ocugen focuses on gene therapies for blindness diseases.

How can I access the conference call?

The conference call can be accessed via a live webcast on Ocugen's investor website.

What time is the Ocugen conference call scheduled?

The conference call is scheduled for 8:30 a.m. ET.

Last updated: Oct 22, 2026